Tandem Diabetes Care (TNDM) Liabilities and Shareholders Equity (2016 - 2025)
Tandem Diabetes Care's Liabilities and Shareholders Equity history spans 13 years, with the latest figure at $881.1 million for Q4 2025.
- For Q4 2025, Liabilities and Shareholders Equity fell 8.94% year-over-year to $881.1 million; the TTM value through Dec 2025 reached $3.6 billion, down 6.58%, while the annual FY2025 figure was $881.1 million, 8.94% down from the prior year.
- Liabilities and Shareholders Equity reached $881.1 million in Q4 2025 per TNDM's latest filing, up from $874.7 million in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $1.1 billion in Q4 2022 to a low of $754.3 million in Q1 2021.
- Average Liabilities and Shareholders Equity over 5 years is $930.4 million, with a median of $940.5 million recorded in 2023.
- Peak YoY movement for Liabilities and Shareholders Equity: soared 119.7% in 2021, then decreased 10.27% in 2023.
- A 5-year view of Liabilities and Shareholders Equity shows it stood at $905.1 million in 2021, then increased by 16.31% to $1.1 billion in 2022, then fell by 9.51% to $952.7 million in 2023, then rose by 1.57% to $967.7 million in 2024, then decreased by 8.94% to $881.1 million in 2025.
- Per Business Quant, the three most recent readings for TNDM's Liabilities and Shareholders Equity are $881.1 million (Q4 2025), $874.7 million (Q3 2025), and $875.7 million (Q2 2025).